Since its inception in 1985, the company and its precursors have benefited from circa $100 million investment in diagnostic and vaccine-related technology research and development.
The fruit of that investment was the precursor and now the proven CPSPVP platform. In several Norwegian and international human clinical studies, Immunor has developed and tested HIV vaccine candidates Vacc-4x, Vacc-C5 (to be combined as Vacc-45). In combination with its HIV entry inhibitor drug, CRX, Immunor now has designed the world’s first vaccine-drug functional cure for HIV. The statistically significant clinical results for Vacc-4x are still the best clinical results for any HIV vaccine.
Immunor – a time-line
| Year | Event |
|---|---|
| 1985 | Immunor founded as Bionor AS in Skein, Norway |
| 1999 | Vacc-4x first human trials |
| 2000 | Vaccine development spun off and Bionor Immuno AS established |
| 2004 | Grant of Vacc-4x patent in US |
| 2010-2011 | Vacc-4x demonstrated a reduction of viral load (secondary endpoint) of 64% in a 135-patient placebo controlled, randomized Phase II trial. Primary endpoints in the study not met so development put on hold until analysis of secondary endpoints were known. |
| 2011 | Research agreement with Celgene of Phase II trial of Revlimid and Vacc-4x |
| 2012 | Vacc-C5 first human trials – Phase I/II trial initiated |
| 2012 | Grant of funds from GLOBVAC and initiation of the Vacc-4x Phase II Reboost trial |
| 2013 | Launch of «Shock & Kill» therapeutic strategy |
| 2014 | Immunor AS incorporated in Norway (22 October) |
| 2015 | Romidepsin supply agreement with Celgene for BIOSKILL clinical trial |
| 2015 | Successful completion of the treatment phase of the REDUC clinical trial |
| 2018 | Preclinical proof of concept CRX (HIV Entry inhibitor) |
| 2020 | Biovacc-19 patent submitted (precursor to BioVac-19R) |
| 2020 | Biovacc-19 Preclinical study |
| 2020 | Preclinical study of Vacc-C5 with new adjuvant |
| 2021 | Licence agreement with Vulsana Ltd to develop neuropathy-wound healing injectable drug |
| 2023 | Development agreement with Professor Cecilia Nauclér on CMV oncogenic virus therapies |
| 2023 | All research and patents gathered under the Immunor platform |